Pfizer in Talks to Acquire Seagen in Deal Likely Valued at More Than $30 Billion

The potential deal, likely valued at more than $30 billion, would help Pfizer add to its lineup of cancer treatments.

The Wall Street Journal | Dirección | Farmacia |

Leer noticia completa en el medio original
Spanish